Literature DB >> 6299557

Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy.

L Einhorn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6299557     DOI: 10.1016/s0305-7372(82)80037-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

Review 1.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

3.  Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.

Authors:  M Pomeroy; J J Fennelly; M Towers
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Nabilone: an alternative antiemetic for cancer chemotherapy.

Authors:  A M Dalzell; H Bartlett; J S Lilleyman
Journal:  Arch Dis Child       Date:  1986-05       Impact factor: 3.791

Review 5.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

Review 6.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

7.  Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.

Authors:  Eric P Baron; Philippe Lucas; Joshua Eades; Olivia Hogue
Journal:  J Headache Pain       Date:  2018-05-24       Impact factor: 7.277

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.